GERON CORP (GERN) Stock News

Geron to Participate at Upcoming Investor Conferences in March 2025

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 Analysts Assess Geron: What You Need To Know

Geron to Announce Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025

Analyst Scoreboard: 4 Ratings For Geron

GERN Stock Earnings: Geron Meets EPS, Beats Revenue for Q2 2024

GERN stock results show that Geron met analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Announces Positive CHMP Opinion for RYTELO™ (imetelstat) for the Treatment of Adults with Transfusion-Dependent Anemia due to Lower-Risk MDS

Geron Announces New IMerge Analyses Presented at ASH Suggesting Clinical Activity of RYTELO™ (imetelstat) in Patients with Lower-Risk MDS Regardless of Type or Number of Prior Therapies

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline Therapy in Patients with Myelofibrosis

Geron to Participate in the 7th Annual Evercore ISI HealthCONx Conference

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Announces Appointment of Joseph Eid, M.D. as Executive Vice President, Research and Development

Geron to Participate in the Stifel 2024 Healthcare Conference

Geron (GERN) Q3 2024 Earnings Call Transcript

GERN earnings call for the period ending September 30, 2024.

Royalty Pharma to Acquire Royalty Interest in Geron’s RYTELO for $125 Million

Mentions: RPRX

Geron Corporation Announces Up to $375 Million in Funding with Royalty Pharma and Pharmakon Advisors

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Geron Announces New Data to be Presented at Upcoming ASH Annual Meeting Highlighting the Potential of RYTELO™ (imetelstat) in Myeloid Hematologic Malignancies

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron to Announce Third Quarter 2024 Financial Results on November 7, 2024

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron Corporation Announces Appointment of Jim Ziegler as Chief Commercial Officer

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Geron (GERN) Q2 2024 Earnings Call Transcript

GERN earnings call for the period ending June 30, 2024.

Geron Corporation Reports Second Quarter 2024 Financial Results and Business Highlights

Geron Announces Updated NCCN Guidelines® Recommending RYTELO™ (imetelstat) for the Treatment of Symptomatic Anemia in Patients with Lower-Risk MDS

Geron Corporation Announces Chief Commercial Officer to Depart at End of August 2024

Geron to Announce Second Quarter 2024 Financial Results on August 8, 2024

3 Under-$10 Biotech Stocks That Could Make You Rich

Discover three under-$10 biotech stocks with potential to make you rich with huge returns on investment through an in-depth analysis.

Mentions: ATNM IOVA MRK BMY

3 Longevity Stocks to Buy for Anti-Aging Breakthroughs

Longevity stocks are at the forefront of combating age-related illnesses with transformative AI-driven drug discovery.

Mentions: DNLI RXRX NVDA

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)